CAS: 16413-26-6; 3-Cyanophenylisocyanate

该化合物是一种多用途芳香异丙氰酸化合物,其特点是在苯环的元体位置上存在一个环状的半雄性异丙氰酸化合物.这一功能性组群增强了它的回活动性,使其成为有机合成中的宝贵中间体,特别是用于制作尿素,碳酸盐和其他异丙氰酸化合物.在受控制的条件下,它的高度纯度和稳定性确保了药物,农用化学品和特殊聚合物等应用的一贯性.该半雄性组体的电子提取性质影响其回活动性,能够进行选择性转换.适当的处理由于其湿度敏感性和潜在的刺激性,是至关重要的.

结构式图片

相似化合物

621-29-4 54132-75-1 51163-27-0

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号620-22-4 间甲基苯腈 | CAS号1877-72-1 3-氰基苯甲酸 | CAS号75-44-5 光气 | CAS号2237-30-1 3-氨基苯甲腈 | CAS号65448-74-0 methyl N-(3-cya... | CAS号87597-64-6 N-(3-CYANOPHENY...

合成工艺路线路线简述

    📜3-氰基苯甲酸置于二苯基磷酸,三乙胺体系中,用 甲苯 用作溶剂,化学反应生成异氰酸间氰基苯酯
    参考文献:Ym022类似物的生物活性.1,4-苯并二氮杂-2-酮作为胃泌素/胆囊收缩素-B受体拮抗剂的新型(3-氨基取代的苯基)脲衍生物.
    标题:Ym022类似物的生物活性.1,4-苯并二氮杂-2-酮作为胃泌素/胆囊收缩素-B受体拮抗剂的新型(3-氨基取代的苯基)脲衍生物.
    摘要:已经制备了有效的胃泌素/胆囊收缩素(cck)-B受体拮抗剂ym022的一系列(3-取代的苯基)脲类似物.该系列的构效关系研究表明,许多类似物对胃泌素/ Cck-B受体具有非常好的体外效能.特别地,与十二指肠内(id)给药相比,Ym022是(3-氨基取代的苯基)脲衍生物(10-12)在大鼠中由五肽胃泌素诱导的胃酸分泌的更有效抑制剂.
    Doi:10.1248/cpb.44.1412

    海关参考信息

    专利信息


    专利号:US-8188113-B2
    优先权日:2006-09-14
    标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
    发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
    权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
    摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

    专利号:US-9833457-B2
    优先权日:2008-01-25
    标题:Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
    发明人：MJALLI ADNAN M M; GADDAM BAPU; POLISETTI DHARMA RAO; KOSTURA MATTHEW J; GUZEL MUSTAFA
    权利人:VTV THERAPEUTICS LLC
    摘要:The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to psoriatic arthritis.

    专利号:MX-2010007768-A
    优先权日:2008-01-25
    标题 :TRICICLIC COMPOUNDS AS MODULATORS OF THE SYNTHESIS OF THE ALFA TUMOR NECROSIS FACTOR AND AS INHIBITORS OF PHOSPHODIESTERASE 4.

    专利号:WO-2009094528-A1
    优先权日:2008-01-25
    标 题:TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS

    专利号:US-2012172381-A1
    优先权日:2008-01-25
    标题 :Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors

    专利号:US-2018071297-A1
    优先权日:2008-01-25
    标题 :Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1038/ncomms14193|10.1038/ncomms15273
    摘要:Pegoraro S, Duffey M, Otto TD, Wang Y, Rösemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M. Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications. 2017 Apr 06;8(1):15273. doi: 10.1038/ncomms15273.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知